×
About 913 results

ALLMedicine™ Ca 125 Center

Research & Reviews  272 results

Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
https://clinicaltrials.gov/ct2/show/NCT03100006

Jun 13th, 2022 - This study tests the hypothesis that the combination of Oregovomab and Nivolumab will improve intracellular Cancer Antigen (CA) 125 antigen processing and elicit a stronger systemic CA 125-specific T cell response; in a manner that is synergistic,...

Treatment of advanced ovarian cancer with carboplatin and paclitaxel in a patient under...
https://doi.org/10.1111/hdi.13020
Hemodialysis International. International Symposium on Ho... Yang Q, Han E et. al.

May 19th, 2022 - A 69-year-old woman under maintenance hemodialysis was diagnosed with advanced ovarian cancer. We treated the patient with combination chemotherapy using paclitaxel and carboplatin. She experienced grade 4 thrombopenia on day 8 of the third course...

Endometrial Cancer Treatment Protocols
https://emedicine.medscape.com/article/2001830-overview

May 18th, 2022 - Treatment Protocols Treatment protocols for endometrial cancer are provided below, including the following: General treatment recommendations Recommendations for limited, metastatic, recurrent, and high-risk disease Risk classifications General tr...

Endometrial Cancer Treatment Protocols
https://emedicine.medscape.com/article/2001830-print

May 18th, 2022 - Treatment protocols for endometrial cancer are provided below, including the following: General treatment recommendations Recommendations for limited, metastatic, recurrent, and high-risk disease Risk classifications General treatment recommendati...

see more →

Guidelines  1 results

Guideline No. 403: Initial Investigation and Management of Adnexal Masses.
https://doi.org/10.1016/j.jogc.2019.08.044
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Salvador S, Scott S et. al.

Aug 2nd, 2020 - To aid primary care physicians, emergency medicine physicians, and gynaecologists in the initial investigation of adnexal masses, defined as lumps that appear near the uterus or in or around ovaries, fallopian tubes, or surrounding connective tiss...

see more →

Clinicaltrials.gov  49 results

Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
https://clinicaltrials.gov/ct2/show/NCT03100006

Jun 13th, 2022 - This study tests the hypothesis that the combination of Oregovomab and Nivolumab will improve intracellular Cancer Antigen (CA) 125 antigen processing and elicit a stronger systemic CA 125-specific T cell response; in a manner that is synergistic,...

Comparison of Operated Ruptured and Non-ruptured Endometriomas
https://clinicaltrials.gov/ct2/show/NCT05348070

Apr 27th, 2022 - This study aims to compare the findings in patients who had surgery for ruptured endometrioma with the patients who had an unruptured endometrioma. This study was conducted at Republic of Turkey Ministry of Health, Health Science University Etlik ...

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT05311579

Apr 13th, 2022 - This is a phase II trial to explore efficacy and safety of niraparib in combination with anlotinib based on CA 125 level in newly diagnosed ovarian cancer. After completion of 1st-line platinum-based chemotherapy with a normal CA-125 concentration...

Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum Cancer
https://clinicaltrials.gov/ct2/show/NCT04826029

Dec 10th, 2021 - This is a randomized multi-center study. Randomization will be stratified on two major prognostic factors: The BRCA mutation (germline or somatic) the serous high or low grade histological subtype of histological se topical (defined according to m...

miRNAs in High Grade Serous Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT05146505

Dec 6th, 2021 - High grade serous ovarian cancer represents the gynecological malignancy with the highest incidence of mortality. Decision-making tools are currently limited to the use of standard imaging modalities and analysis of serum biomarkers, such as CA 12...

see more →

News  40 results

Case Scenario: Stage 3C High-Grade Serous Ovarian Cancer
https://www.onclive.com/view/case-scenario-stage-3c-high-grade-serous-ovarian-cancer

Feb 3rd, 2022 - Chad A. Hamilton, MD: The second case is a 64-year-old who received frontline chemotherapy with the carbo [carboplatin]/Taxol [paclitaxel] for a stage IIIC high-grade serous epithelial ovarian cancer. This is our kind of bread-and-butter patient. ...

Expert Discusses Immunotherapy Across Gynecologic Malignancies
https://www.onclive.com/view/expert-discusses-immunotherapy-across-gynecologic-malignancies

Oct 6th, 2021 - Dmitriy Zamarin, MD, PhD Immunotherapy is slowly evolving in the gynecologic malignancies landscape and has moved beyond only having a role in ovarian cancer, according to Dmitriy Zamarin, MD, PhD. For example, pembrolizumab (Keytruda) has shown...

Secondary Debulking Surgery in Ovarian Cancer
https://www.onclive.com/view/secondary-debulking-surgery-in-ovarian-cancer

Apr 2nd, 2021 - Transcript: Bradley J. Monk, MD, FACOG, FACS: Let’s transition to secondary debulking. Brian, tell us a little bit about the passion of the Germans and the DESKTOP sort of idea. What are they thinking, and what is the idea of a secondary opera...

Patient Selection: Adjuvant Therapy and Testing for ES NSCLC
https://www.onclive.com/view/patient-selection-adjuvant-therapy-and-testing-for-es-nsclc

Apr 2nd, 2021 - Benjamin P. Levy, MD: Who gets this, and for how long? Dr Leal, you’re not considering doing it yet, but let’s say you’ve decided that you’re going to give it routinely. Whom would you give it to, and for how long would you give the drug to them? ...

Tips for Talking With Patients: "Mother Question" and Sleep Test
https://www.onclive.com/view/tips-for-talking-with-patients-mother-question-and-sleep-test

Dec 5th, 2020 - Maurie Markman, MD Not surprisingly, as a longtime practicing oncologist specializing in gynecological cancer, I have noticed that certain themes and questions about individualized, scientifically unanswerable dilemmas often recur when I talk to ...

see more →

Patient Education  3 results see all →